The association of increased p14 ARF/p16 INK4a and p15 INK4b gene expression with proliferative activity and the clinical course of multiple myeloma

Haematologica

Volumn 91, Issue 11, 2006, Pages 1551-1554

  Sarasquete, María Eugenia ^a   García Sanz, Ramón ^a,b   Armellini, Adriana ^a   Fuertes, Marta ^b   Martín Jiménez, Patricia ^a   Sierra, Magdalena ^b   Chillón, María Del Carmen ^a   Alcoceba, Miguel ^a   Balanzategui, Ana ^a   Ortega, Fernando ^b   Hernández, José Mariano ^b   Sureda, Anna ^b   Palomera, Luis ^b   González, Marcos ^a   San Miguel, Jesús F ^a,b  

^a HOSPITAL UNIVERSITARIO DE SALAMANCA   (Spain)

^b Grupo Español de Mieloma GEM PETHEMA   (Spain)

Author keywords

Gene expression; Multiple myeloma; p14 ARF; p15 INK4B; p16 INK4A; Real time quantitative PCR

Indexed keywords

CYCLIN DEPENDENT KINASE INHIBITOR; CYCLIN DEPENDENT KINASE INHIBITOR 2B; PROTEIN P14ARF; PROTEIN P15; PROTEIN P16INK4A; UNCLASSIFIED DRUG;

ARTICLE; CELL PROLIFERATION; CONTROLLED STUDY; DISEASE COURSE; GENE EXPRESSION; HUMAN; HUMAN CELL; MAJOR CLINICAL STUDY; MULTIPLE MYELOMA; POLYMERASE CHAIN REACTION; PROTEIN EXPRESSION; TREATMENT OUTCOME; BIOSYNTHESIS; COMPARATIVE STUDY; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; MIDDLE AGED; PATHOLOGY; PROGNOSIS; UPREGULATION;

CELL PROLIFERATION; CYCLIN-DEPENDENT KINASE INHIBITOR P15; CYCLIN-DEPENDENT KINASE INHIBITOR P16; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MIDDLE AGED; MULTIPLE MYELOMA; PROGNOSIS; TUMOR SUPPRESSOR PROTEIN P14ARF; UP-REGULATION;

EID: 33750944336     PISSN: 03906078     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (18)

1. Chen-Kiang S. Biology of plasma cells. Best Pract Res Clin Haematol 2005;18:493-507.
2. Garcia-Sanz R, Gonzalez-Fraile MI, Mateo G, Hernandez JM, Lopez-Berges MC, de Las HN, et al. Proliferative activity of plasma cells is the most relevant prognostic factor in elderly multiple myeloma patients. Int J Cancer 2004;112:884-9.
3. Bergsagel PL, Kuehl WM, Zhan F, Sawyer J, Barlogie B, Shaughnessy J, Jr. Cyclin D dysregulation: an early and unifying pathogenic event in multiple myeloma. Blood 2005;106:296-303.
4. Lee MH, Yang HY. Regulators of G1 cyclin-dependent kinases and cancers. Cancer Metastasis Rev 2003;22:435-49.
5. Quelle DE, Zindy F, Ashmun RA, Sherr CJ. Alternative reading frames of the INK4a tumor suppressor gene encode two unrelated proteins capable or inducing cell cycle arrest. Cell 1995;83:993-1000.
6. Hirama T, Koeffler HP. Role of the cyclin-dependent kinase inhibitors in the development of cancer. Blood 1995;86:841-54.
7. Mateos MV, Garcia-Sanz R, Lopez-Perez R, Moro MJ, Ocio E, Hernandez J, et al. Methylation is an inactivating mechanism of the p16 gene in multiple myeloma associated with high plasma cell proliferation and short survival. Br J Haematol 2002;118:1034-40.
8. Kramer A, Schultheis B, Bergmann J, Willer A, Hegenbart U, Ho AD, et al. Alterations of the cyclin D1/pRb/p16(INK4A) pathway in multiple myeloma. Leukemia 2002;16:1844-51.
9. Zhan F, Hardin J, Kordsmeier B, Bumm K, Zheng M, Tian E, et al. Global gene expression profiling of multiple myeloma, monoclonal gammopathy of undetermined significance, and normal bone marrow plasma cells. Blood 2002;99:1745-57.
10. Giulietti A, Overbergh L, Valckx D, Decallonne B, Bouillon R, Mathieu C. An overview of real-time quantitative PCR: applications to quantify cytokine gene expression. Methods 2001;25:386-401.
11. Bladé J, Lahuerta JJ, Sureda A, Diaz Mediavilla J, Garcia Laraña J, Alegra A, et al. High-dose therapy/stem cell support in multiple myeloma. Update of the Spanish studies (PETHEMA-GEM). Haematologica 2005;90:38-9.
12. Greipp PR, San Miguel J, Dune BG, Crowley JJ, Barlogie B, Blade J, et al. International staging system for multiple myeloma. J Clin Oncol 2005;23:3412-20.
13. Blade J, Samson D, Reece D, Apperley J, Bjorkstrand B, Gahrton G, et al. Criteria for evaluating disease response and progression in patients with multiple myeloma treated by high-dose therapy and haemopoietic stem cell transplantation. Myeloma Subcommittee of the EBMT. European Group for Blood and Marrow Transplant. Br J Haematol 1998;102:1115-23.
14. Gabert J, Beillard E, van dV, V, Bi W, Grimwade D, Pallisgaard N. et al. Standardization and quality control studies of 'real-time' quantitative reverse transcriptase polymerase chain reaction of fusion gene transcripts for residual disease detection in leukemia - a Europe Against Cancer program. Leukemia 2003;17:2318-57.
15. Mateo MG, San Miguel JF, Orfao A. Immunophenotyping of plasma cells in multiple myeloma. Methods Mol Med 2005;113:5-24:5-24.
16. Lust JA, Donovan KA. Biology of the transition of monoclonal gammopathy of undetermined Significance (MGUS) to multiple myeloma. Cancer Control 1998;5:209-217.
17. Hirama T, Koeffler HP. Role of the cyclin-dependent kinase inhibitors in the development of cancer. Blood 1995;86:841-54.
18. Davies FE, Dring AM, Li C, Rawstron AC, Shammas MA, O'Connor SM, et al. Insights into the multistep transformation of MGUS to myeloma using microarray expression analysis. Blood 2003;102:4504-11.